Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Szkultecka-Dębek, Monika" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Real world data supporting identification of the pharmacist’s role in obesity and overweight treatment in Poland – a preliminary report
Autorzy:
Drozd, Mariola
Bułaś, Lucyna
Szkultecka-Dębek, Monika
Skowron, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/454892.pdf
Data publikacji:
2017
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
overweight
obesity
pharmaceutical care
treatment, real world data
Opis:
Introduction. Obesity is a significant health and economic problem, both for the patient and the health care system. An essential element in the prevention and treatment of each disease is the engagement of all groups of healthcare professionals. In our study, we performed an analysis of the real world data, obtained from a survey of the medical and socioeconomic problems associated with overweight and obesity. We aimed to identify the pharmacist’s role in the management of overweight and obese patients, including their individualized education in an outpatient setting. Material and methods. The study material consisted of responses obtained from a specially designed questionnaire. Our findings indicate that the study patients had easy access to a pharmacist’s professional knowledge, relevant to comprehensive treatment of obesity. In addition, our data indicates a lack of patient knowledge of a healthy lifestyle and an inability to implement such knowledge in practice. Results. The community pharmacist should actively provide support to patients with obesity (including the primary obesity and those who want to lose excessive body mass for health-related and also for aesthetic reasons) and the management of their weight. The results of our study should be considered as an introduction to further research to facilitate the understanding of problems and expectations of patients and to prepare pharmacists to perform pharmaceutical care (PC) in this regard. Conclusion. One of the potential options to protect society against the obesity epidemic is an education about the risks inherent to obesity and promotion of a healthy lifestyle.
Źródło:
European Journal of Clinical and Experimental Medicine; 2017, 3; 192-199
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The direct costs of drug-induced skin reactions
Autorzy:
Kiepurska, Nina
Paluchowska, Elwira
Owczarek, Witold
Szkultecka-Dębek, Monika
Jahnz-Różyk, Karina
Powiązania:
https://bibliotekanauki.pl/articles/989873.pdf
Data publikacji:
2017
Wydawca:
Instytut Medycyny Wsi
Tematy:
adverse drug reactions
direct costs
icd 10
jgp
national health fund
Opis:
Objective. The aim of the study was an assessment of direct costs of patients hospitalised for for skin adverse drug reactions during 2002–2012 in the Department of Dermatology at the Military Institute of Medicine (Ministry of Defence) in Warsaw. The analysis was carried out from the perspectives of the public payer and service provider. Materials and method. The retrospective study was carried out in a group of 164 adult patients due to skin adverse drug reactions. Analysis was based on data from patient medical records and medical orders which provided information on the used resources, including diagnostic tests, medical consultations, medicinal products, hospitalisation duration, together with cost estimation, regardless of the treatment being the cause of the skin reaction. Results. According to the International Statistical Classification of Diseases and Related Health Problems(ICD) diagnosis and scores, assigned by the National Healthcare Fund, it has been estimated that patient hospitalisation at the Department of Dermatology for skin drug reaction incurred costs at the average amount of €717.00 per patient. The complex diagnostics and pharmacotherapy of the same group of patients generated costs for the hospital at the average amount of €680 per patient. Conclusions. As a result of the analysis, the therapy for skin adverse drug effects generates significant costs, both for the payer and the service provider. Since the costs are comparable, it seems that the pricing of medical procedures by the public payer is adequate for the costs incurred by the medical service provider.
Źródło:
Annals of Agricultural and Environmental Medicine; 2017, 24, 2
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies